<p>Neoadjuvant chemotherapy (NAC) for breast cancer is widely employed. We performed genome-wide association studies (GWAS) to determine if germline genetic variability was associated with benefits, in terms of pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS), in patients entered on the NSABP B-40 NAC (National Surgical Adjuvant Breast and Bowel Project, B-40, Neoadjuvant Chemotherapy) trial where some patients were randomized to receive bevacizumab, in addition to chemotherapy. </p>

Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics

2 selected publications including "Bevacizumab added to neoadjuvant chemotherapy for breast cancer." (460 citations)

Neoadjuvant Chemotherapy +/- Bevacizumab Pharmacogenomics

Bevacizumab added to neoadjuvant chemotherapy for breast cancer.

Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.